Effect of Dapagliflozin on VT in Patients With Heart Failure.

• Status: Not yet recruiting
• Trial end date: 2024-11-15
• Target enrollment: 0
• Participant gender: All

Summary

This project plans to design a randomized controlled clinical trial to evaluate the effect of dapagliflozin on ventricular arrhythmia in the participants with heart failure with reduced ejection fraction after ICD implantation by collecting and analyzing the data of ECG, cardiac ultrasound and ICD programming. This project will explore the anti-ventricular arrhythmia effect of dapagliflozin in HFrEF patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Treatments: Dapagliflozin

Criteria

Inclusion Criteria:

patients received ICD therapy with HFrEF, including: ischemic cardiomyopathy, non-ischemic cardiomyopathy, LVEF ≤35% and optimized anti-HF therapy for at least 6 months.

Exclusion Criteria:

1. Type 1 diabetes or a history of repeated diabetic ketoacidosis.

2. Those who strictly restrict carbohydrate intake.

3. Genital infection.

4. Low blood pressure.

5. SGLT2i allergy.

6. Severe renal impairment or end-stage renal disease (eGFR<30ml/(min•1.73m^2)) or dialysis.

7. The water-electrolyte and acid-base balance disorders have not been corrected.

8. Bladder cancer.

9. Those taking other antiarrhythmic drugs except beta-blockers.

10. Other diseases cause the patient's life expectancy to be less than 1 year.